PhysioAssist announces successful acquisition by Inogen Inc. to accelerate Simeox’ US market reach and beter serve a larger population of obstructive respiratory patients.

Simeox^TM by PhysioAssist is a commercial breakthrough respiratory device, aimed at offering better care to chronic respiratory patients.

PhysioAssist acquisition by Inogen was successfully closed on September 14, 2023.

erieux Equity Partners, the lead investor since 2017, Relyens Innovation Santé (advised by Turenne Capital), Région Sud Investissement (société financière de la Région Sud, financée en partie par l’Europe) , CAAP Creation and BPM have actively supported the product development and the early commercial phase of the company and are proud to hand over to a leading global player in oxygen therapy market for bringing beter care solutions to more patients.

PhysioAssist has developed a range of innovative solutions tackling the problem of airway clearance for patients suffering from chronic lung diseases thanks to a unique technology, enabling drainage of the most distal mucus without any inflammation. Simeox^TM is the first global connected care solution in homecare airway clearance to improve chronic respiratory patients’ quality of life.

The acquisition provides PhysioAssist with enhanced resources, expertise, and a broader network to expand its reach and impact on a global scale.

I am very excited about PhysioAssist joining the Inogen group. This is a significant milestone in the journey to scale up the Simeox innovative product offerings globally to the benefit of bronchiectasis and cystic fibrosis patients. Inogen is the market leader in portative oxygen concentrators, with a strong footprint in US which is the next growth driver for Simeox device. This acquisition is the best opportunity and the entire team at PhysioAssist is very enthusiastic in the future synergies with Inogen.

Adrien Mithalal, CEO of PhysioAssist

I’m particularly proud of what the team at PhysioAssist has achieved and of the part we have played in this successful trajectory. This acquisition, happening when the M&A deals in the global medical devices industry are decreasing for several quarters and are very selective, confirms the uniqueness of the technology and the highly differentiated features of the products. I’m a strong believer in the capacity of the combined teams to accelerate Simeox^TM market reach and to continue to bring highly efficient and innovative products to the patients.

Dr. Valérie Calenda, Managing Partner at Merieux Equity Partners

We are very happy to have accompanied PhysioAssist in this venture with 2000 SIMEOX placed in Europe of which 90% in a homecare setting thanks to Adrien and his team with the help of Anne Reiser, PhysioAssist chairwoman previously EMEA head at Resmed. The Inogen operation thanks to its operational presence in Europe and in the USA should accelerate this momentum and a wider use of this technology across new countries and indications.

Mounia Chaoui, partner at Turenne Capital